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Abstract
The sequence selectivity of 14 classical protein-tyrosine phosphatases (PTPs) (PTPRA, PTPRB,
PTPRC, PTPRD, PTPRO, PTP1B, SHP-1, SHP-2, HePTP, PTP-PEST, TCPTP, PTPH1, PTPD1,
and PTPD2) was systematically profiled by screening their catalytic domains against
combinatorial peptide libraries. All of the PTPs exhibit similar preference for pY peptides rich in
acidic amino acids and disfavor positively charged sequences, but differ vastly in their degrees of
preference/disfavor. Some PTPs (PTP-PEST, SHP-1, and SHP-2) are highly selective for acidic
over basic (or neutral) peptides (by >105-fold), whereas others (PTPRA and PTPRD) show no to
little sequence selectivity. PTPs also have diverse intrinsic catalytic efficiencies (kcat/KM values
against optimal substrates), which differ by >105-fold due to different kcat and/or KM values.
Moreover, PTPs show little positional preference for the acidic residues relative to the pY residue.
Mutation of Arg47 of PTP1B, which is located near the pY-1 and pY-2 residues of a bound
substrate, decreased the enzymatic activity by 3–18-fold toward all pY substrates containing acidic
residues anywhere within the pY-6 to pY+5 region. Similarly, mutation of Arg24, which is
situated near the C-terminus of a bound substrate, adversely affected the kinetic activity of all
acidic substrates. A co-crystal structure of PTP1B bound with a nephrin pY1193 peptide suggests
that Arg24 engages in electrostatic interactions with acidic residues at the pY+1, pY+2, and likely
other positions. These results suggest that long-range electrostatic interactions between positively
charged residues near the PTP active site and acidic residues on pY substrates allow a PTP to bind
acidic substrates with similar affinities and the varying levels of preference for acidic sequences
by different PTPs are likely caused by the different electrostatic potentials near their active sites.
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The implications of the varying sequence selectivity and intrinsic catalytic activities with respect
to PTP in vivo substrate specificity and biological functions are discussed.
Keywords
Combinatorial library; catalytic activity; kinetics; phosphotyrosine; PTP; substrate specificity
Protein-tyrosine phosphatases (PTPs) are a large family of enzymes that catalyze the
hydrolysis of phosphotyrosine (pY) in proteins to tyrosine and inorganic phosphate. The
human genome encodes 107 putative PTPs, with the class I cysteine-based PTPs constituting
the largest group.1 This group is divided into 61 dual-specificity phosphatases (DUSPs) and
38 tyrosine-specific or ‘‘classical” PTPs. The latter can be further classified into the receptor
and nonreceptor subgroups. Dysregulation of PTPs is associated with a multitude of
diseases, and many members of the PTP family have been recognized as potential
therapeutic targets.2,3 PTPs are actively involved in cell signaling, capable of either turning
signaling pathways on or off.1–5 To date, over 15000 pY sites on >6000 mammalian
proteins have been reported,6 which are presumably dephosphorylated by the 107 PTPs. The
large number of PTPs and potential substrate proteins suggests that PTPs must have some
level of substrate specificity in vivo in order to achieve fidelity for the signaling pathways in
which they are involved. Currently, the prevailing view is that PTPs have “exquisite
substrate specificity” in vivo. However, how PTPs achieve such specificity is not well
understood. It has been proposed that the substrate specificity of PTPs is controlled
combinatorially by the intrinsic sequence specificity of the catalytic domain and other
regulatory mechanisms, including specific tissue distribution, restricted subcellular
localization, posttranslational modification events (e.g., phosphorylation), and accessory or
regulatory domains (e.g., KIM motifs or SH2 domains).7,8 For receptor PTPs,
homodimerization (and possibly, heterodimerization) provides yet another potential
mechanism to regulate the PTP activity.9
There have been many previous attempts to define the intrinsic sequence selectivity (or
“active-site specificity”) of PTPs and its contribution to the overall PTP substrate specificity
in vivo.10 However, this has been a challenging task because the PTP active site interacts
with at least 3–5 residues on either side of pY; definition of PTP sequence selectivity
requires the analysis of a large number of pY peptide sequences. We recently developed a
combinatorial peptide library approach for systematically profiling the sequence selectivity
of PTPs.10–12 In this study, we applied the peptide library method to profile the intrinsic
sequence selectivity of 4 receptor [PTPRB (RPTPβ), PTPRC (CD45), PTPRD (RPTPδ), and
PTPRO (GLEPP1)] and 6 nonreceptor PTPs [(HePTP (PTPN7), PTP-PEST (PTPN12),
TCPTP (PTPN2), PTPH1 (PTPN3), PTPD1 (PTPN21), and PTPD2 (PTPN14)].
Surprisingly, these PTPs, as well as 3 out of the 4 PTPs we have studied previously (PTP1B,
SHP-1, and SHP-2),11 all have a similar preference for pY peptides rich in acidic residues
(e.g., Asp and Glu) and disfavor positively charged sequences, but do not exhibit simple
consensus sequences. Kinetic analyses of the 14 PTPs against model pY-peptide substrates
showed that the PTPs have vastly different catalytic properties. The molecular basis of this
unusual sequence selectivity was further investigated by site-directed mutagenesis and X-ray
crystallographic studies. Our results suggest that long-range electrostatic interactions
between basic residues near the PTP active site and acidic residues flanking the pY residue
on peptide substrates are responsible for the unusual sequence selectivity of PTPs. They also
suggest that PTPs likely have varying levels of substrate specificity in vivo, and some PTPs
might take advantage of their low intrinsic catalytic efficiencies to achieve selective
dephosphorylation of target proteins.
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MATERIALS AND METHODS
Materials
Reagents for peptide synthesis were purchased from Advanced ChemTech (Louisville, KY),
AAPPTec (Louisville, KY), Chem-Impex (Wood Dale, IL), or Peptides International
(Louisville, KY). N-(9-Fluorenylmethoxycarbonyloxy)succinimide was purchased from
Advanced ChemTech. α-Cyano-4-hydroxycinnamic acid, phenyl isothiocyanate, and 3-
methyl-2-benzothiazolinonehydrazone (MBTH) were obtained from Sigma-Aldrich. Nα-
Fmoc-O-t-butyl-3,5-difluorotyrosine (F2Y) was synthesized as described previously.13
Tyrosinase from Streptomyces antibioticus was expressed in Escherichia coli and purified as
described previously.10
Purification of PTPs
The catalytic domains of wild-type and mutant PTP1B (amino acids 1–321) and SHP-1 (aa
205–595) were expressed in Escherichia coli and purified as previously described.10,14
PTPD2 (aa 876–1187), PTPRA (aa 224–802), and PTPRC (aa 620–1236), all containing an
N-terminal histidine tag, and SHP-2 (aa 199–593) and PTPD1 (aa 875–1174), each
containing a C-terminal histidine tag, were expressed in E. coli and purified as described.15
TCPTP (aa 1–314), PTP-PEST (aa 5–300), PTPRB (aa 1686–1971), HEPTP (aa 22–335),
PTPH1 (amino acids 628–909), PTPRD (aa 1299–1899), and PTPRO PTP domain were
expressed in E. coli as fusion proteins with glutathione-S-transferase (GST) and purified as
described previously.15,16 Protein concentrations were determined by the Bradford method,
using bovine serum albumin (BSA) as the standard.
Library Screening
Peptide libraries I–V (Table 1) were synthesized on polyethylene glycol acrylamide resin
(0.4 mmol/g; 150–300 µm diameter in water), as described previously.10 In a typical
screening experiment, 15 mg of the appropriate peptide library (dry weight, ~45,000 beads)
was placed in a plastic micro-BioSpin column (2 mL, Bio-Rad) and extensively washed with
DMF and ddH2O. The resin was blocked for 1 h with blocking buffer (30 mM Hepes, pH
7.4, 150 mM NaCl, 0.01% Tween 20, and 0.1% gelatin). The library was then incubated
with a given PTP (final concentration 0.5–800 nM) in blocking buffer containing 5 mM
tris(carboxyethyl)phosphine (TCEP) (total volume 0.8 mL) at room temperature for 5–30
min with gentle mixing. The resin was drained, washed with 0.1 M KH2PO4 (pH 6.8), and
resuspended in 1.6 mL of 0.1 M KH2PO4 (pH 6.8) containing 1.2 µM tyrosinase and 6 mM
3-methyl-2-benzothiazolinonehydrazone (MBTH). The resulting mixture was incubated at
room temperature with gentle mixing and exposure to air. Intense pink/red color typically
developed on positive beads after 20–60 min. Positive beads were retrieved from the library
using a micropipette under a dissecting microscope, and sequenced by the partial Edman
degradation-mass spectrometry (PED-MS) method.17 Control experiments without PTPs
produced no red beads under otherwise identical conditions. Detailed conditions for
individual screening experiments are provided in Table S1 in Supporting Information (SI).
Synthesis of Selected Peptides
Individual peptides were synthesized on 100 mg of CLEAR-amide resin using standard
Fmoc/HBTU/HOBt chemistry. For coupling of pY, 2.0 equivalents of Fmoc-Tyr(PO3H2)-
OH were employed, whereas 4.0 equivalents were used for all other amino acids. Resin-
bound peptides were washed with dichloromethane, cleaved from the resin, and deprotected
using modified reagent K [7.5% phenol, 5% water, 5% thioanisole, 2.5% ethanedithiol, and
1% anisole in trifluoroacetic acid (TFA)] at room temperature for 2 h. After evaporation of
solvents, the mixture was triturated three times with 20 volumes of cold Et2O. Precipitates
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were collected and dried under vacuum, and crude peptides were purified by reversed-phase
HPLC on a semi-preparative C18 column. The identity of each peptide was confirmed by
MALDI-TOF mass spectrometric analysis.
PTP Assays
PTP activities were determined by two different methods. For method A, assay reactions
were performed in a quartz microcuvette (total volume 120 µL) containing 100 mM HEPES,
pH 7.4, 50 mM NaCl, 2 mM EDTA, 1 mM TCEP, 0.1 mg/mL BSA, and 0–1.4 mM pY
peptide. The reaction was initiated by the addition of PTP (final concentration 0.5–20000
nM) and monitored continuously at 282 nm (Δε = 1102 M−1 cm−1 ) on a UV-VIS
spectrophotometer. Initial rates were calculated from the early regions of the reaction
progress curves (typically <60 s). Data fitting against the Michaelis-Menten equation V =
Vmax · [S]/(KM + [S]) or the simplified equation V = kcat[E][S]/KM (when KM >> [S]) gave
the kinetic constants kcat, KM, and/or kcat/KM. For method B, reactions were performed
similarly, but reaction progress was monitored continuously at 282 nm until the substrate
was depleted. The kinetic constants were obtained by directly fitting the reaction progress
curves against equation:
where t is time, p is the product concentration at time t, [E] is the total enzyme
concentration, and p∞ is the product concentration at infinity.18
Pre-Steady State Kinetics
Pre-steady-state kinetic experiments were carried out by rapidly mixing the PTP and p-
nitrophenyl phosphate (pNPP) in a temperature-controlled Applied Photophysics SX20
stopped-flow spectrophotometer equipped with a detector of 5-mm path length, and
monitoring reaction progression at 410 nm. The reactions contained 100 mM Tris, pH 7.4,
50 mM NaCl, 2 mM EDTA, 1 mM TCEP, and 20 mM pNPP (final concentration).
Experiments with PTPD1 contained 10 µM enzyme (final concentration) and were carried
out at 4 °C, whereas PTPD2 reactions were performed with 5 µM enzyme (final
concentration) at 25 °C. The rate constants (kburst and kcat) were determined by fitting the
experimental data (Abs values as a function of time) against the equation:
where A and B are the amplitudes of the bursts, kburst is the first-order rate constant of the
initial burst, t is the time, k1’ is the first-order rate constant of the conformational change, C
is the slope of the final linear phase of the curve, and D is the y-intercept of the linear phase
of the curve. The kcat value was calculated from slope C according to the equation: kcat =
C / (ε • [E]) where ε is the molar absorptivity of pNPP at 410 nm (10,000 M−1 cm−1) and [E]
is the enzyme concentration. The kinetic constants k2 and k3 were determined using the
equations kburst = k2 + k3 and kcat = k2 • k3/(k2 + k3).
Crystallization and Data Collection
The purified catalytically inactive C215S PTP1B (aa 1–321) was co-crystallized with the
peptide Ac-AWGPLpYDEVQM-NH2 (where M is L-norleucine) at 4 °C by hanging drop
vapor diffusion. The catalytic domain (10 mg/mL) in 0.1 M HEPES (pH 7.0) and 50 mM
NaCl was mixed with 10-fold molar excess of peptide dissolved in water. The hanging drops
Selner et al. Page 4
Biochemistry. Author manuscript; available in PMC 2015 January 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
were prepared by mixing 2 µL of the complex and 2 µL of the reservoir solution, which
consisted of 14.4 % PEG 8000, 0.1 M HEPES (pH 7.5), and 0.2 M MgCl2. Thin needle
crystals grew after one week. For X-ray data collection, crystals were transferred to a cryo-
protectant solution containing the reservoir solution supplemented with 25% glycerol. A
single crystal was mounted on a nylon loop and plunged in liquid nitrogen. X-ray diffraction
data were collected at the LRL-CAT beamline 31-ID of the Advanced Photon Source,
Argonne National Laboratory. Diffraction data were integrated and scaled using MOSFLM
and SCALA of the CCP4 suite.19
Structure Determination
The structure was determined by molecular replacement with MOLREP of the CCP4 suite
using the structure of the free PTP1B catalytic domain [Protein Data Bank (PDB) entry
1PTY] as the search model.19 After an initial round of refinement at 1.74 Å using
REFMAC5 of the CCP4 suite,20 electron density maps revealed strong density for the pY
residue of the nephrin peptide, which was built into the model using COOT.21 Several
additional rounds of refinement and model building led to the final model consisting of
residues 2–298 of the PTP1B catalytic domain (chain A), and residues pY–3 to pY+2 of the
nephrin peptide (chain B). Data collection and refinement statistics are listed in Table 4.
Structural figures were prepared using CCP4MG.22
RESULTS
Peptide Library Design and Screening
Five different peptide libraries were employed in this work (Table 1). Each PTP was first
screened against library I and/or II. Library I contains five random residues N-terminal to
pY, ASXXXXXpYAABBRM-resin [where B is β-alanine and X is F2Y (used as a Tyr
surrogate), norleucine (Nle or M, used as a replacement of Met), or any of the 19
proteinogenic amino acids except for Tyr, Met, or Cys]. Library II, which is similar to
library I but contains eight random residues N-terminal to pY, was designed to test whether
residues beyond pY-5 (relative to pY, which is defined as position 0) affect PTP activity
and/or specificity. Library III has 10-fold reduced Arg and Lys content, but is otherwise
identical to library I. When screened against library I or II, some PTPs (e.g., PTPRA10)
selected predominantly Arg- and Lys-rich sequences, which had poor activity when tested
against the PTPs in solution. This bias was likely caused by multi-dentate, electrostatic
interactions between the positively charged sequences and negatively charged surface
patches on the PTPs,23 resulting in recruitment of greater amounts of PTPs to the “false
positive” beads. We previously showed that reduction of Arg and Lys content in the library
by 10-fold effectively eliminated the Arg-and Lys-rich sequences, allowing the specificity
profile of PTPRA to be determined.10 For most of the PTPs examined in this work (except
for PTP-PEST), screening against library II or III produced sequence data of the highest
quality, which are presented below. Library IV contains five random residues C-terminal to
pY (Alloc-AApYXXXXXNNBBRM-resin), whereas library V contains five random
residues on each side of pY (Alloc-AXXXXXpYXXXXXNNBBRM-resin). Library V was
designed to test whether a PTP requires specific sequences on both N- and C-terminal sides
of pY for activity and/or exhibits covariance between the N- and C-terminal sequences.
Libraries I, III, and IV have a theoretical diversity of ~2.5 × 106, whereas libraries II and V
have theoretical diversities of 1.7 × 1010 and 6.1 × 1012, respectively. All peptide libraries
were synthesized in the one-bead-one-compound (OBOC) format on polyethylene glycol
acrylamide (PEGA) resin (150–300 µm in water, ~3 × 106 beads/g of dry resin). Library
screening involved treatment of a portion of the library beads (typically 15 mg of dry resin
in each reaction) with a limited amount of PTP so that only beads that display the most
efficient substrates underwent significant dephosphorylation. The optimal PTP concentration
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and reaction time were determined by trial and error and varied greatly depending on the
catalytic efficiency of the PTP (Table S1). After termination of the PTP reaction (by
washing the library beads with a buffer), the exposed Tyr side chain was oxidized into an
orthoquinone by incubation with tyrosinase in the presence of O2.10,11 The orthoquinone
was captured in situ by MBTH to form a reddish pigment, which remained covalently
attached to the beads. Both tyrosinase and MBTH were used in excess to ensure that the
coloration reaction went to completion. The tyrosinase exhibits no sequence selectivity.10
Positive (red) beads were isolated manually from the library with a micropipette and were
sequenced individually by using the PED-MS method.17
PTPs Have Similar Specificity Profiles
A total of 45 mg of library II was screened against 500 nM HePTP in three separate
experiments. Sequencing of the intensely, medium, and lightly red beads gave 61, 106, and
99 complete (and some partial) sequences, respectively (Table S2). HePTP was also
screened against library IV (30 mg resin in 2 experiments), producing 50 complete
sequences (Table S3). HePTP strongly preferred a hydrophilic residue (especially Asp and
Glu) at the pY-1 position (Figure 1a); 42 out of the 61 sequences (69%) derived from
intensely colored beads, which represent the most efficient HePTP substrates, had Asp or
Glu at this position, whereas most of the remaining sequences contained Asn, Gln, Thr, and
Ser. The absence of large hydrophobic amino acids (e.g., Try and Phe) at the pY-1 position
makes HePTP a notable exception among the classical PTPs studied so far. It also has strong
preference for acidic residues at positions pY+1 and pY+2 and modest preference for acidic
residues at all other positions (Figure 1a and Figure 2a). Note that the number of beads/
sequences screened against HePTP represents only a small fraction of the entire sequence
space (0.0008% and 3.6% for library II and IV, respectively). We have previously
demonstrated that randomly sampling a small fraction of a combinatorial peptide library is
sufficient to unambiguously determine the specificity profiles of protein binding domains,24
protein kinases,25 and protein phosphatases.10–12
Screening of the PTP-PEST catalytic domain against libraries I and III produced 96
sequences (Table S4 in SI). PTP-PEST strongly prefers acidic residues, Asn, or Ser at the
pY-2 and pY-3 positions (Figure 1b). Unlike HePTP, it prefers a hydrophobic residue (e.g.,
Trp, Ile, Phe) at the pY-1 position and either acidic or hydrophobic residues at the pY-4 and
pY-5 positions. To determine the C-terminal specificity, PTP-PEST was also screened
against library V, which features five random residues on each side of pY. Again, PTP-
PEST exhibited overwhelming preference for acidic sequences; each of the 39 selected
sequences contained two or more acidic residues, which occurred most frequently at the pY
+2, pY+1, pY-3, and pY-2 positions (Figure 3a and Table S5). Only 7/135 sequences
selected from the two libraries contained an Arg, Lys, and/or His residue, and these residues
usually occupied less critical positions (e.g., pY-5 and pY+5).
Initial screening of PTPH1 against library II generated exclusively Arg- and Lys-rich
sequences, which had poor activity when tested against PTPH1 in solution (Table S6 and
vide infra). To alleviate this screening bias, we screened PTPH1 against library III, which
has a reduced Arg and Lys content (by 10-fold). Screening of library III against PTPH1
produced 138 preferred sequences, which were rich in aromatic hydrophobic (e.g., Trp, Tyr,
and Phe) and, to a lesser extent, acidic residues (Table S7 and Figure 1c). Remarkably, no
Arg or Lys was found in any of the 138 sequences, indicating that PTPH1 strongly disfavors
basic pY peptides as substrate. The X-ray structure of PTPH1 shows that it has a highly
positively charged surface surrounding the active site, but highly negatively charged
surfaces elsewhere.15
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TCPTP behaved similarly to PTPH1 in that screening against library I produced many Arg-
and Lys-rich sequences (Table S8). When screened against library III, it selected peptides
rich in acidic and aromatic hydrophobic residues. However, despite the 10-fold reduced Arg
and Lys content, the selected peptides contained a fair number of Arg and His residues,
suggesting that TCPTP is more tolerant to basic amino acids than PTPH1 (Table S9 and
Figure 1d). Screening of the C-terminal library (library IV) gave 26 acidic sequences and 45
basic sequences, consistent with the notion that TCPTP has very broad sequence specificity
and is relatively tolerant to basic sequences (Table S10 and Figure 2b).
PTPD2 was screened against libraries III and IV (Table S11 and Table S12, respectively).
Compared to other PTPs, substantially higher PTPD2 concentration (800 nM) and longer
reaction time (60 min) were necessary to generate positive beads (Table S1). It strongly
prefers Ile or other hydrophobic residues at the pY-1 position and has moderate preference
for acidic and aromatic hydrophobic residues at the pY-2 to pY-5 positions (Figure 1e). Like
PTPH1, PTPD2 appears to strongly disfavor basic sequences on the N-terminal side of pY.
On the C-terminal side, it favors Tyr or Trp at the pY+1 position and acidic residues at the
pY+2 position (Figure 2c). Library screening against PTPD1 failed to produce positive
beads under the conditions employed in this work (500 nM PTPD1 for 60 min), suggesting
that it has low catalytic activity toward all peptide substrates.
The four receptor PTPs showed very similar, broad specificity profiles (Table S13–18,
Figure 1f–1i, and Figure 3b–3c). They all have moderate to weak preference for acidic and
aromatic hydrophobic residues. PTPRB is unique in that it prefers an Asp (but not Glu)
residue at the pY-1 position and tolerates small hydrophilic (e.g., Ser, Thr, Asn) but not
basic (Arg, Lys, and His) residues at this position. It has moderate preference for acidic
residues at pY-2 and pY-3 and aromatic hydrophobic residues at the pY-4 and pY-5
positions. PTPRD appears to be somewhat more tolerant to basic residues than the other 3
receptor PTPs, as indicated by the larger number of Arg and Lys residues selected.
Overall, the 10 PTPs examined in this study and three out of the four PTPs previously
investigated (SHP-1, SHP-2, and PTP1B) show similar specificity profiles: they all prefer
acidic and large hydrophobic amino acids and disfavor basic residues. The only exception is
PTPRA, which exhibits little sequence selectivity.10 Surprisingly, none of the 14 PTPs
exhibit any consensus sequence(s); the preferred acidic and hydrophobic residues were
found at essentially any of the positions proximal to the pY residue (pY-8 to pY+5).
PTPs Exhibit Diverse Kinetic Properties and Different Degrees of Preference for Acidic
Sequences
Since most of the PTPs (except for PTPRA) prefer acidic/hydrophobic sequences and
disfavor basic ones, we assayed the 14 PTPs against a generic set of peptide substrates, Ac-
YDEDFpYDYEF-NH2 (acidic), Ac-SASASpYSASA-NH2 (neutral), and Ac-
YRKRFpYRYKF-NH2 (basic) to quantitatively assess their preference for acidic sequences
and tolerance for basic ones. Remarkably, and in contrast to their similar specificity profiles,
these PTPs displayed vastly different kinetic properties, with their intrinsic catalytic
efficiencies differing by up to 2 × 105-fold (Table 2). The most active enzyme, PTP-PEST,
had a kcat/KM value of 2.2 × 108 M−1 s−1 toward the acidic peptide, whereas the least active
enzyme (PTPD1) had a value of only 1.2 × 103 M−1 s−1. The different catalytic efficiencies
were caused both by differences in kcat, which ranged from 470 s−1 (PTP-PEST) to 0.032
s−1 (PTPD1) and/or by different KM values, which varied from 0.28 to 280 µM (or 1000-
fold). Overall, PTP-PEST, SHP-1, SHP-2, PTP1B, TCPTP, PTPH1, PTPRB, PTPRC, and
PTPRO are highly efficient enzymes (kcat/KM values ≥6.8 × 106 M−1 s−1), whereas HePTP,
PTPD1, PTPRA, and PTPRD have much lower intrinsic activity (kcat/KM values ≤7.5 × 104
M−1 s−1) (Table 2). Interestingly, PTPD2, which was previously reported to lack significant
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activity in vitro,15 is actually a rather efficient catalyst, having an intrinsic activity (kcat/KM)
of 1.1 × 105 M−1 s−1. However, like PTPD1, it has an unusually low kcat value (0.073 s−1),
which probably made previous kinetic measurements (performed with less efficient
substrates) difficult. Second, while all of the PTPs (with the exception of PTPRA) preferred
acidic over basic sequences (Figure 1), their degree of preference/disfavor varied greatly. On
one end of the spectrum, PTP-PEST, SHP-1, and SHP-2 were highly selective for acidic
substrates, having kcat/KM values for Ac-YDEDFpYDYEF-NH2 ~105-fold higher than that
of Ac-YRKRFpYRYKF-NH2 (Table 2 and 3). Their intermediate activities toward the
neutral substrate (Ac-SASASpYSASA-NH2) indicate that these PTPs engage in attractive
and repulsive interactions with acidic and basic sequences, respectively, as expected from
the highly positive electrostatic potential surrounding their active sites.15 By contrast,
PTPRA was almost completely insensitive to the substrate sequence, having essentially the
same activity toward acidic, neutral, and basic peptides. Other PTPs showed intermediate
selectivity for acidic sequences (21–2600-fold higher kcat/KM values for acidic than basic
substrate). For some of the PTPs (e.g., PTPD1 and PTPRD), the selectivity is presumably
the result of attractive interactions with acidic substrates, because they have similar activities
toward neutral and basic substrates (Table 3). Other PTPs (e.g., PTPH1 and PTPD2) show
relatively little discrimination between acidic and neutral substrates but strongly disfavor
basic sequences. As a result of these specificity differences, the 14 PTPs have markedly
different abilities for dephosphorylating various types of substrates. For example, PTP-
PEST is 2930-fold more active than PTPRA toward peptide Ac-YDEDFpYDYEF-NH2 but
is 30-fold less active toward peptide Ac-YRKRFpYRYKF-NH2.
PTPs are Insensitive to the Position of Acidic Residues
To confirm the observation from library screening that PTPs prefer acidic and hydrophobic
residues but are insensitive to their positions relative to pY, we examined the kinetic
activities of SHP-1, SHP-2, and PTP1B toward a panel of peptide substrates that contain a
similar number of acidic and hydrophobic residues at different positions. As shown in Table
4, SHP-1 had similar activity toward peptides WAGDDpY, FDIDIpY, EIFDFpY, and
FYDIDpY (≤2-fold difference in kcat/KM values), which each contain two acidic residues
and 1–3 hydrophobic residues at different positions N-terminal to pY. The importance of the
acidic residues in substrate binding and catalysis is underscored by its 100–200-fold lower
activity toward the neutral peptide SASASpYSASA. SHP-2 showed the same trend (Table
4). PTP1B, which has moderate preference for acidic sequences, also had similar kcat/KM
values toward a panel of acidic pY peptides.10 We chose PTP1B for further analysis,
because its intermediate level of preference for acidic sequences is more representative of
the classical PTP subfamily and various PTP1B mutants were already available.14,26 To this
end, we synthesized and tested five additional pY peptides that contained acidic residues at
very different positions, from the extreme N-terminus (EEDNAWpYAA) to the C-terminus
(AApYWAYDD), against PTP1B (Table 4, entries 12–16). Again, all five acidic peptides
were highly active toward PTP1B and had very similar kinetic activities (with kcat/KM
values of 1–2 × 107 M−1 s−1), which were 5–10-fold higher than that of the neutral peptide
SASASpYSASA. On the basis of these kinetic and specificity profiling data,10,27 we
propose that the general preference for acidic sequences that lack a specific consensus motif
may be a common feature of all PTPs.
Arg47 and Arg24 of PTP1B Engage in Long-Range Interactions with Acidic Residues in pY
Substrates
A potential explanation for the unique sequence selectivity pattern of PTPs may be that the
acidic residues in pY substrates engage in long-range electrostatic interactions with basic
residues (Arg and Lys) surrounding the PTP active site. Because charge-charge interaction,
which decreases linearly with the distance between opposite charges, is relatively distance
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insensitive, an acidic residue on a bound pY peptide may interact with all of the Arg and Lys
residues near the PTP active site and generate similar overall binding energies irrespective
of its precise location in the substrate. Conversely, a positively charged residue near the PTP
active site may interact with all acidic residues that are proximal to the pY. Thus, the degree
of preference/disfavor for acidic/basic sequences by a PTP would be dictated by the overall
electrostatic potential surrounding its active site. To test this notion, we assayed a panel of
pY peptides containing acidic amino acids at varying positions against WT, R47E, and
R24M PTP1B variants. Arg47 is located ~8 Å from the pY-binding pocket (i.e., the distance
between Cα atoms of Arg47 and pY of a bound peptide) and interacts electrostatically with
acidic residues at the pY-1 and pY-2 positions.28–30 Arg24 is located near the C-terminal
region of a bound pY peptide and is ~15 Å away from the pY residue (Cα-Cα). When a
bound substrate contains a tandem pY motif (pYpY), Arg24 has been shown to interact with
the side chain of the second pY residue.30 However, whether Arg47 and Arg24 interact with
other substrate residues was previously unknown.
Mutation of Arg47 or Arg24 had little effect on the PTP1B catalytic activity toward pNPP or
the neutral peptide SASASpYSASA (Tables 5 and 6), indicating that the R47E and R24M
mutations do not affect the overall stability or the active-site structure of PTP1B. By
contrast, the R47E mutation decreased the catalytic activity of PTP1B by 3–18-fold toward
all acidic substrates, including those containing acidic residues at the extreme N- (e.g.,
EEDNAWpYAA) or C-terminus (e.g., AApYAAADD) (Table 5). The largest decrease
occurred for peptide ASSDEpYAA (18-fold), which contains acidic residues at the pY-1 and
pY-2 positions. This is consistent with the previous observation that Arg-47 is located near
the pY-1 and pY-2 residues of a bound substrate.28–30 Note that both WT and R47E mutant
PTP1B variants had, within the experimental error, essentially the same kcat value (~35 s−1)
toward all peptide substrates, and that the mutation primarily affected the KM values. These
results suggest that Arg47 engages in favorable electrostatic interactions with acidic residues
located anywhere within the pY-6 to pY+5 region to enhance the substrate binding affinity.
Consistent with this notion, the R47E mutation resulted in increased PTP1B activity toward
the positively charged peptide ARKRIpYAA (by 5-fold), suggesting that either Arg47
engages in repulsive interactions with the positively charged residues in the pY peptide and/
or Glu47 in the mutant enzyme favorably interacts with the Arg/Lys residues of the substrate
peptide. Previous studies with R47A and R47E mutants demonstrated that both repulsive
and attractive interactions contribute to the difference in activity toward peptide
DADEpYLIPQQG.14
Similarly, the R24M mutation decreased the PTP1B activity toward all acidic substrates, but
not toward the neutral peptide SASASpYSASA (Table 6). In general, the mutation had a
greater effect on substrates containing acidic residues on the C-terminal side of the pY
residue, especially those with acidic residues at the pY+1 and pY+2 positions, consistent
with its physical proximity to these two residues in the crystal structure.28–30 As expected,
the R24M mutation slightly increased the PTP1B activity toward peptide AApYIRKRA (by
1.6-fold), indicating that Arg24 engages in repulsive interaction with the positively charged
residues C-terminal to pY. Note that peptides containing an acidic amino acid at the pY+1
position generally had poorer activity toward PTP1B, especially against the R24M mutant
(e.g., peptides AApYDDIDE and AApYDDAAA). This is in agreement with a previous
report that PTP1B disfavors acidic residues at the pY+1 position,27 but in apparent
contradiction with our observation that Arg24 interacts most strongly with an acidic residue
at the pY+1 or pY+2 position.
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Structural Basis for Long-Range Interactions between Arg47/Arg24 and Acidic Residues in
pY Substrates
Many PTP-pY peptide co-crystal structures have been reported, most of which involved
substrates containing acidic residues N-terminal to pY.28–34 To gain a structural basis for the
observed interactions between the Arg24/Arg47 residues of PTP1B and acidic residues C-
terminal to pY, and to reconcile the apparent contradiction mentioned above, we determined
the X-ray crystal structure of PTP1B in complex with a peptide containing acidic residues
on the C-terminal side of pY. A recently discovered PTP1B substrate, nephrin, contains two
pY sites with acidic residues immediately C-terminal to pY, AWGPLpY1193DEVQM and
DPRGIpY1217DQVAG.35 Both peptides were efficient substrates of PTP1B and the R24M
mutation resulted in substantial reduction of their activities toward PTP1B (2.3- and 7.6-
fold, respectively) (Table 6). The nephrin pY1193 peptide was co-crystallized with
catalytically inactive C215S mutant PTP1B and the structure of the complex was solved at
1.7 Å resolution to an R factor of 0.170 (Table 7). In the structure, PTP1B residues 2–298
and nephrin peptide residues pY-3 to pY+1 were clearly resolved and these five substrate
residues were fit unambiguously to the electron density (Figure 4A). A region of electron
density was also observed next to the pY+1 residue and tentatively fit with the sidechain
carboxyl group of pY+2 Glu. As observed in previous PTP1B-pY peptide structures,28–30
the nephrin peptide bound to PTP1B in the canonical orientation with the peptide backbone
in an extended β-strand conformation (Figure 4B). The pY residue was bound to the pY-
binding loop in the usual manner with the phosphate forming close interactions with the
guanidino group of Arg-221, several backbone amides of the pY-binding loop (residues
217–221), and the N-terminal end of the α-helix that follows (Figure 4C and Figure S1 in
SI). The pY peptide backbone forms three hydrogen bonds with PTP1B, two from the
carboxylate group of Asp-48 to the NH groups of the pY and the pY+1 residues, and a third
from the backbone carbonyl of the pY-2 residue to the backbone amide of Arg-47 (Figure
4C and S1). Based on the electron density maps, the Arg24 side chain was modeled in two
alternative conformations (Figure S2 in SI). In the first conformation, the guanidinium group
of Arg24 forms a hydrogen bond with the carboxylate group of the pY+1 Asp, which is also
hydrogen bonded to the side chain amine of Gln262 (Figure 4C and S1). When in the
alternative conformation, the Arg24 side chain points toward and presumably interacts
electrostatically with the pY+2 Glu side chain (Figure S2). The side chain of Arg-47, which
is positioned near the pY-1 residue, was not well resolved in the structure, and was therefore
truncated to alanine in the final refined model. However, the side chain of Leu at the pY-1
position adopts a similar conformation as previously reported by Sarmiento et al.,29 which is
favorable for hydrophobic interactions with the aliphatic portion of the Arg-47 side chain.
The disorder of the Arg-47 side chain in this structure potentially reflects the fact that the
residues at the pY-1 and −2 positions were Leu and Pro, respectively, instead of acidic
residues. As observed in previous structures,28–30 Arg-47 can make specific interactions
with acidic residues at these positions.
To assess the potential contribution of long-range electrostatic interactions between
Arg47/24 and acidic residues on pY substrates to catalysis, we replaced each residue of the
nephrin pY1193 peptide in the co-crystal structure with an Asp and measured the minimal
and maximal possible distances between the Asp and Arg side chains, assuming that both
Arg and Asp side chains can rotate freely into different energetically allowable
conformations. The same modeling exercise was also carried out with a previously reported
co-crystal structure of PTP1B bound with a consensus peptide Ac-ELEFpYMDYE-NH2, in
which substrate residues from pY-3 to pY+4 were well resolved.29 The distances derived
from the two structures were rather similar and consistent with the kinetic results (Table 8).
Arg47 had the shortest distance from Asp at the pY-3 and pY-1 positions (~1 Å), but was
also within 3.5–10 Å from Asp residues at the pY-2 to pY+4 positions. Given that the
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backbone of the pY peptides binds to the surface of PTP1B in essentially an identical
manner in all structures so far determined, it is unlikely that Arg47 could make direct
hydrogen bonding interactions with acidic residues at the pY+1 to pY+5 positions. We
conclude that Arg47 engages in long-range electrostatic interactions with the acidic residues
C-terminal to pY, enhancing the kinetic activity of the peptide substrate. Similarly, Arg24
can potentially form a hydrogen bond with an Asp residue at the pY+1 position, but is too
far for direct hydrogen bonding with acidic residues at other positions. Again, the distances
between Arg24 and these other acidic residues (6–15 Å) are well within the range for
significant electrostatic interactions. The PTP1B-nephrin peptide structure shows that
several other basic residues are within 17 Å distance from the active site, including Arg45,
Arg254, Lys36, Lys41, Lys116, and Lys120 (Figure 4D). These residues likely also engage
in favorable electrostatic interactions with acidic residues of pY peptides, although the
amount of binding energy they provide might be smaller, given their overall longer distances
from a bound substrate.
Finally, we examined two previously reported PTP-pY peptide structures that contained
acidic residues C-terminal to pY (Figure S3 in SI). We found that in the structure of
lymphoid-specific PTP (LYP) bound with peptide YGEEpYDDLY (pdb: 3OLR),34 both
Asp residues of the bound peptide point toward the side chain of Lys32 (Figure S3 in SI).
Similarly, in the structure of PTPRC (CD45) in complex with peptide REEpYDV (pdb:
1YGR),31 the side chains of pY-1 Glu and pY+1 Asp both point toward the side chain of
Arg637 (Figure S3). We propose that long-range electrostatic interactions are involved in
the E•S complex formation for these PTPs as well.
C-Terminal Sequence Is the Primary Specificity Determinant for PTP-PEST
Screening of PTP-PEST against library V resulted in a greater number of acidic residues on
the C-terminal side of pY than the N-terminal side (15, 13, 19, and 21 Asp/Glu residues at
positions pY-3, pY-2, pY+1, and pY+2, respectively), suggesting that the C-terminal
sequence is the primary determinant of PTP-PEST substrate specificity (Table S5). This
notion was confirmed by assaying PTP-PEST against peptides containing acidic residues on
either the N- or C-terminal side of pY: Ac-ASSDEpYAA-NH2 and Ac-AApYDLDEY-
NH2). These two substrates exhibited kcat/KM values of 7.2 × 106 and 1.3 × 108 M−1 s−1,
respectively; notably, the latter value approaches that of the most active PTP-PEST substrate
(2.2 × 108 M−1 s−1 for Ac-YDEDFpYDYEF-NH2). Therefore, PTP-PEST is unique among
the classical PTPs, which usually have their major specificity determinant on the N-terminal
side of pY (e.g., PTP1B, SHP-1, and SHP-2).10,36 The only other PTP superfamily member
known to have its major specificity determinant located on the C-terminal side of pY is the
dual specificity phosphatase VH1.37
PTPD1 and PTPD2 Are Highly Active Under Single Turnover Conditions
Compared with most of the other PTPs, PTPD1 and PTPD2 have very low intrinsic catalytic
efficiencies in vitro due to unusually low kcat values. Nevertheless, their catalytic activities
are both necessary and sufficient for their in vivo functions.38,39 In an attempt to reconcile
this apparent contradiction, we conducted pre-steady-state kinetic analysis to determine the
reason for their low kcat values. PTP catalysis involves the formation of a covalent
phosphocysteinyl-enzyme intermediate (E-PO32-), and the overall reaction rate (kcat) is
determined by both its formation (k2) and decay (k3) (Scheme 1A).40,41
Rapid mixing of PTPD1 (10 µM) and a saturating concentration of pNPP (20 mM) in a
stopped-flow apparatus at 4 °C produced a reaction progress curve that consisted of a rapid
initial phase (0–100 ms) and a slow final phase (>3 s) (Figure 5). Experiments at 25 °C
failed to resolve the initial phase, which was too fast for the instrument used in this work (k
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>100 s−1 ). Our initial attempt to fit the experimental data to the kinetic model in Scheme 1A
was unsuccessful (due to inability to fit data in the 0–0.2 s region). The data, however, could
be fit to a model that assumes a mixture of two different populations of PTPD1, with the
first having the kinetic mechanism illustrated in Scheme 1A and the other having the
mechanism in Scheme 1B, which predicts an additional conformational change converting
either the free enzyme (E*) or the initial E*•S complex into the catalytically competent form
(E or E•S). Curve fitting yielded rate constants for formation of the covalent intermediate
(kburst = 39 s−1), conformational change (k1’ = 0.68 s−1 ), and decay of the phosphoenzyme
intermediate (kcat = 0.0012 s−1). The microscopic rate constants k2 and k3 of PTPD1 were
determined from the kburst and kcat values, and are 39 s−1 and 0.0012 s−1 , respectively. The
amplitudes of the two burst phases (A = 0.027 and B = 0.0025 absorbance units) suggest an
~10:1 ratio of the two enzyme populations. The putative conformational change might
involve the cis-trans isomerization of a peptidyl-prolyl bond (e.g., that of the WPD/E motif
that provides a critical general acid/base during catalysis4). There are many examples of
proteins existing as a mixture of peptidyl-prolyl cis and trans isomers.42 Additional studies
will be necessary to reveal the structural basis of the putative conformational change, which
is not the focus of this study. Experiments with PTPD2 showed similar burst kinetics and a
very fast initial phase (k2 ≥110 s−1). Thus, for both PTPD1 and PTPD2, breakdown of the
covalent intermediate (k3, or a step after that) is rate-limiting and responsible for their
unusually low kcat values (kcat ≈ k3). However, both enzymes are highly active under single
turnover conditions (high k2 values). In fact, their k2 values are similar to those of other
highly proficient PTPs (e.g., a k2 value of 193 s−1 at 3.5 °C for Yersinia PTP, which is one
of the most active PTPs known to date43). Note that the k2 values of PTPD1 and PTPD2 are
expected to be still higher for preferred peptide and protein substrates. The fact that PTPD1
and PTPD2 have similar kcat values of toward Ac-YDEDFpYDYEF-NH2, Ac-
SASASpYSASA-NH2, and pNPP, which have vastly different kcat/KM values (Table 2 and
Table S19 in SI), is consistent with the above conclusion.
DISCUSSION
In this and a previous study,10 we have systematically profiled the sequence selectivity for
14 out of the 38 classical human PTPs by screening combinatorial peptide libraries.
Surprisingly, 13 of the PTPs exhibit similar specificity profiles in that they all prefer acidic
and large hydrophobic amino acids and disfavor basic residues, although they do have subtle
differences at certain positions (e.g., HePTP prefers an acidic residue, whereas PTP-PEST,
PTPD2, PTPRD, and PTPRO prefer a hydrophobic amino acid at the pY-1 position). On the
other hand, these PTPs differ drastically in their intrinsic catalytic efficiency and degree of
preference/disfavor for acidic/basic sequences. Furthermore, unlike proteases and protein
kinases, the PTPs do not exhibit any consensus sequence(s), even for those that are highly
selective for acidic sequences (e.g., PTP-PEST, SHP-1, and SHP-2). Apparently, acidic
residues located anywhere between the pY-8 and pY+5 positions (the region tested in this
study) contribute favorably to substrate binding and catalysis.
What is the molecular basis of this unusual sequence selectivity? We found that removal of
the side chain of Arg47 or Arg24 reduced the catalytic activity of PTP1B toward pY
peptides containing acidic residues anywhere between the pY-6 and pY+5 positions. The co-
crystal structures of PTP1B bound with two different peptides revealed that acidic residues
located at most of the above positions are too distant to form direct hydrogen bonds with the
arginine residues. Therefore, we conclude that Arg47 and Arg24 engage in long-range
electrostatic interactions with acidic residues on the pY peptides and the R47E and R24M
mutations eliminate the favorable electrostatic interactions and, in the case of the former,
likely generate repulsive interactions with the acidic substrates. Although not examined in
this study, Arg45, Arg254, Lys36, Lys41, Lys116 and Lys120 are also located near the
Selner et al. Page 12
Biochemistry. Author manuscript; available in PMC 2015 January 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
bound pY substrates (Figure 4D) and expected to engage in similar electrostatic interactions
with acidic residues in the substrates. Unlike other weak interactions (e.g., van der Waals
forces), charge-charge interaction is relatively insensitive to the distance (1/r) and remains
significant even when a charged pair is separated by 10–20 Å. We propose that the presence
of several Arg/Lys residues “strategically” positioned around the substrate-binding site is
responsible for PTP1B’s lack of significant positional preference for acidic residues. An
acidic residue located anywhere on a bound substrate (pY-6 to pY+5) is expected to interact
with all of the positively charged residues near the PTP active site, but with different
strengths. For example, an acidic residue near the N-terminus (e.g., at position pY-5) would
interact more strongly with Lys41, Arg45, and Arg47 due to their physical proximity to the
pY-5 residue, and weakly with the other, more distal Arg/Lys residues. On the other hand,
an acidic residue at the C-terminus of the peptide (e.g., at position pY+2) may gain most of
its binding energy through interactions with Arg24, Arg47, and Arg254, with less
contribution from Lys41 and Arg45 (Figure 4D). Thus, an Asp residue at position pY-5 or
pY+2 may enhance the overall binding affinity and the kcat/KM value of a substrate by a
similar amount, even though in each case the acidic residue interacts with a different set of
PTP1B residues. This lack of positional preference for acidic residues, together with the
absence of any well-defined substrate-binding pockets/grooves on the PTP surface (other
than the pY-binding pocket),15,28–34 likely endows PTPs with the ability to accommodate a
broad range of peptide sequences (or inability to recognize specific sequence motifs) and
therefore similar specificity profiles. The differential degrees of preference/disfavor for
acidic/basic sequences are likely caused by the different electrostatic potentials at their
substrate-binding sites. Indeed, PTPs that strongly prefer acidic over neutral and basic
substrates (e.g., PTP-PEST, SHP-1, SHP-2) all have highly positively charged surfaces near
their active sites, whereas PTPRA, PTPRD, and PTPD1, which show only weak preference
for acidic substrates, have a mixture of basic and acidic amino acids and overall neutral
electrostatic potential at their substrate-binding sites.15
There have been conflicting reports with regard to PTP1B’s specificity at the pY+1 position.
While several studies showed that a second pY residue at the pY+1 position substantially
enhances PTP1B activity,30,44 inverse alanine scanning suggested that PTP1B prefers a
hydrophobic residue (e.g., Met) and disfavors acidic residues (Asp and Glu) at the pY+1
position.27 The kinetic data in this work confirmed PTP1B’s slight disfavor for Asp and Glu
at the pY+1 position (Table 5, compare entries 12 and 13). Yet, the R24M mutation caused
the largest activity reduction toward substrates containing an acidic residue at the pY+1
position, suggesting that Arg24 contributes significantly to substrate binding and catalysis.
The X-ray structure of PTP1B bound to the nephrin pY1193 peptide provides a potential
explanation for this apparent contradiction. PTP1B possesses a shallow amphipathic pocket
next to the pY-binding pocket, formed by the side chains of Asp48, Val49, Ile219, and
Met258 on the pocket floor and the side chains of Gln262 and Arg24 on one side (Figure 4C
and S4). A hydrophobic side chain such as that of methionine is well accommodated by the
pocket and enhances substrate binding and catalysis through hydrophobic effects (Figure
S4B).29 A pY residue also fits snugly into the pocket, because its phenyl ring interacts with
the hydrophobic surface and the negatively charged phosphate forms salt bridges with
Arg24 (Figure S4A).30 Asp and Glu are not preferred because their side chains do not
interact effectively with the hydrophobic surface and unlike pY, their side chains are too
short to interact favorably with Arg24 (Figure S4C). In order to hydrogen bond with the pY
+1 Asp and neutralize its negative charge (and therefore accommodate it in a hydrophobic
pocket), the side chain of Arg24 moves toward the Asp residue by ~2.3 Å into a presumably
less stable conformation (Figure 4C and S2). The R24M mutation eliminates the charge
neutralization effect, leaving a negatively charged Asp side chain in a largely hydrophobic
pocket. Indeed, the R24M mutant enzyme has unusually low activity toward peptides
containing an acidic pY+1 residue (Table 6).
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Despite PTPs’ broad, similar specificities toward peptide substrates in vitro, numerous
genetic “knock-in” and knockout experiments have demonstrated that at least some PTPs
exhibit substantial substrate specificity in vivo. What factors, then, may enhance the PTPs’
substrate specificity in vivo? We propose that PTPs may utilize their diverse catalytic
properties as yet another strategy, along with sequence selectivity, subcellular localization,
spatial and temporal expression, posttranslational modification, and protein-protein
interaction to achieve in vivo substrate specificity. On the basis of their intrinsic catalytic
efficiency, we divide the 14 PTPs into five different groups and briefly speculate how the
catalytic efficiency may influence their in vivo substrate specificity.
Group I (PTP-PEST, SHP-1, and SHP-2)
These three enzymes are highly active and selective for acidic sequences, while having poor
activity toward neutral sequences and extremely poor activity for basic sequences (Table 2
and Table 3). The intrinsic sequence selectivity of their PTP domains likely plays a key role
in controlling their in vivo substrate specificity. For highly negatively charged pY sites,
which are numerous in the human proteome, substrate recruitment may not be necessary to
achieve efficient dephosphorylation; rather, it will be important to keep their highly
proficient PTP domains in check to avoid unintended reactions. Both SHP-1 and SHP-2
exist in an auto-inhibited state, in which their N-terminal SH2 domain binds
intramolecularly to their PTP active site, sterically blocking substrate access to the catalytic
site.45,46 Binding of their N-SH2 domain to a high-affinity pY ligand activates the PTP
domain by disrupting the auto-inhibitory mechanism and recruits the PTP domain to the
vicinity of the pY ligand.47,48 This mechanism allows the selective dephosphorylation of
acidic pY motifs on the pY-ligand protein and/or other pY proteins in the same signaling
complex. For less acidic or neutral pY motifs (which could contain either all neutral residues
or a combination of positively and negatively charged residues), substrate recruitment
mediated by the SH2 domains (SHP-1 and SHP-2) or proline-rich sequences (PTP-PEST)
should further increase their activity toward specific substrates. However, we envision that it
is unlikely for substrate recruitment to overcome their extremely poor activity toward highly
basic pY sites. Indeed, all of the in vivo SHP-1 and SHP-2 substrates reported to date
contain highly negatively charged pY motifs.10 The reported PTP-PEST substrates, SRC
(IEDNEpY424TARQ),49 FAK (SEIDDpY397AEIID),50 PYK2 (IESDIpY402AEIPD and
IEDEDpY579pY580KASVT),51 WASP (TSKLIpY291DFIED),52 and PSTPIP1
(RNELVpY344ASIEV),53 also all contain negatively charged residues surrounding the pY
sites.
Group II (HePTP, PTPRA, and PTPRD)
PTPs in this group are two to four orders of magnitude less active than most of the other
PTPs (e.g., group I PTPs) due to high KM values, indicating that their active sites bind
poorly to pY substrates. Their “normal” kcat values (i.e., similar to those of most other PTPs)
suggest that once being recruited to a specific substrate via protein-protein interaction (and
thus a reduced KM value), they have the potential to act as highly efficient enzymes (high
kcat/KM values). The lack of sequence selectivity of the PTPRA catalytic domain predicts
that (1) the in vivo substrate specificity of PTPRA is dictated by substrate recruitment and
(2) PTPRA may be capable of hydrolyzing any pY motif recruited to its vicinity, including
highly positively charged sequences. HePTP has moderate sequence selectivity (e.g., it
prefers an acidic amino acid at the pY-1 and pY+1 positions), and its in vivo substrate
specificity is likely determined by both substrate recruitment and the specific peptide
sequence surrounding the pY residue. Therefore, due to their low intrinsic catalytic activity
and inability to hydrolyze pY proteins in the absence of substrate recruitment, HePTP and
PTPRA are expected to function as highly specific enzymes in vivo. This model is in
excellent agreement with the results of previous studies. For example, PTPRA selectively
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dephosphorylates SRC at pY527.54 It was proposed that the SH2 domain of SRC binds to the
pY789 of PTPRA and recruits it to the active site of PTPRA. Other PTPRA substrates, such
as LYN and FYN kinases, contain SH2 domains and are likely recruited via the same
mechanism.55,56 Similarly, HePTP has a kcat/KM value of 4.8 × 103 M−1 s−1 toward the
ERK2 peptide DHTGFLpTEpY187VATRW but dephosphorylates the phospho-ERK2
protein at the same site with a rate of 2.6 × 106 M−1 s−1, because the N-terminal kinase
interaction motif (KIM domain) of HePTP interacts with and recruits ERK2.57 PTPRD also
showed low catalytic activity; unfortunately, we were not able to accurately determine its
kcat or KM value. We tentatively assign it to Group II on the basis of its relatively high kcat
(>0.86 s−1) and KM values (>60 µM) (Table 2).
Group III (PTPD1 and PTPD2)
PTPD1 and PTPD2 are also orders of magnitude less active than most of the other PTPs,
because of their unusually low kcat values (Table 2). Steady-state and pre-steady-state
kinetic data indicate that slow breakdown of the covalent intermediate (k3, or a step after
that) is responsible for the low kcat values. The slow k3 step is likely due to the presence of
atypical residues in their active sites.15 The highly conserved aspartate residue of the WPD
loop, which acts as a critical general base during the k3 step, is replaced by a glutamate in
PTPD1. PTPD2 lacks a highly conserved tyrosine residue in the pY recognition loop.
Because the k3 step is common for all substrates, they will all have the same kcat value
(except for very poor substrates that have k2 as the rate-limiting step), no matter how tightly
they bind to the PTP active site. Thus, substrate recruitment per se is not expected to
increase the maximal reaction rate (Vmax) of PTPD1 or PTPD2 under steady-state
conditions, although we cannot rule out the possibility that substrate binding, interaction
with regulatory proteins, or posttranslational modification may change the conformation of
the PTP domain and increase the k3 value. We propose that PTPD1 and PTPD2 function as
single turnover enzymes in vivo. Because they can only efficiently turnover a substrate once,
we predict that effective dephosphorylation of a specific substrate would require the
formation of a stable, stoichiometric complex with the substrate protein through their non-
catalytic elements (e.g., the FERM domain), and dephosphorylation would be limited to a
single pY residue on the substrate (Figure 6). Since the reaction product presumably remains
associated with the PTP, there is no need (or evolutional driving force) for the
phosphoenzyme intermediate to undergo rapid hydrolysis. In fact, slow regeneration of the
active enzyme enhances substrate specificity because the catalytically inactive
phosphoenzyme cannot dephosphorylate other pY residues on the substrate protein or other
pY proteins in the same signaling complex. Again, previous publications support our
proposal. PTPD1 constitutively associates with SRC and activates the kinase by selective
dephosphorylation of pY527, enhancing growth factor-induced signal transduction.58,59
Presumably, formation of the SRC/PTPD1 complex juxtaposes the pY527 residue (but not
pY416, which is required for full activation of SRC60,61) with the PTPD1 active site. PTPD2
lacking the PTP domain stably associates with β-catenin and overexpression of this
dominant negative mutant induces tyrosine phosphorylation of β-catenin and cell
migration.39 PTPD2 also selectively dephosphorylates pY128 of p130Cas in vitro and in
vivo.62
Group IV (PTP1B, TCPTP, and PTPH1)
PTPs in this group are highly active and have limited sequence selectivity. They can
efficiently dephosphorylate acidic and neutral pY sequences and have respectable activity
even toward the least reactive, highly basic peptides (kcat/KM values of 103–104 M−1 s−1).
Although these enzymes are restricted to specific subcellular locations (PTP1B to the
endoplasmic reticulum,63 TCPTP to the endoplasmic reticulum and nucleus,64,65 and
PTPH1 to the cytoskeleton66), their catalytic domains are still accessible to a wide variety of
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pY proteins in the cytoplasm and/or nucleus. With kcat/KM values of >106 M−1 s−1 for acidic
and neutral pY sequences, they can dephosphorylate 50% of a cellular protein containing
acidic/neutral pY motifs in <5 s (assuming a PTP concentration of 100 nM, which is the
average cellular concentration of signaling proteins67). We propose that PTPs in this group
dephosphorylate a wide variety of pY proteins in their immediate environments to maintain
an overall low level of tyrosyl phosphorylation of cellular proteins. During active cell
signaling, cells are known to produce reactive oxygen species (e.g., H2O2), which may
transiently inactivate these PTPs to allow signal transduction to take place. Notably, a large
number of PTP1B and TCPTP protein substrates have been reported and feature diverse
sequences surrounding the dephosphorylated pY sites.10, 68
Group V (PTPRB, PTPRC, and PTPRO)
The catalytic domains of these receptor PTPs are similar to the group IV enzymes, in that
they are highly efficient PTPs with low sequence selectivity. Obviously, their membrane
localization should facilitate their dephosphorylation of membrane-associated proteins or
proteins transiently recruited to the membrane during cell signaling. How their potent PTP
activity is kept in check is less clear at the present time. Some of them contain a second,
catalytically inactive PTP domain, which can affect the physiological function of the active
PTP domain.69,70 Dimerization provides another mechanism for regulating the activity of
receptor PTPs.9,71 Receptor PTPs may also be regulated by redox signals.72 Finally, their
large extracellular domains may respond to environmental signals and regulate the activity
of the PTP domain.
In conclusion, systematic profiling of 14 classical PTPs allowed us to conclude that most of
the classical PTPs prefer acidic over basic pY sequences as substrates, but differ vastly in
their degree of sequence preference and intrinsic catalytic efficiency. Long-range
electrostatic interactions between positively charged residues near the PTP active site and
acidic residues of a peptide substrate render PTPs insensitive to the positions of acidic
residues in substrates and therefore all having a similar preference for acidic substrates.
Their different levels of preference for acidic substrates are likely caused by the different
overall electrostatic potentials of their substrate-binding sites. Finally, our results suggest
that PTPs may have different levels of substrate specificity in vivo, which are brought about
by a combination of several mechanisms including substrate recruitment and utilization of
low intrinsic catalytic efficiency.
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ABBREVIATIONS
2-aminobutyrate;
F2Y 3,5-difluorotyrosine
Fmoc-OSu N-(9-fluorenylmethoxycarbonyloxy) succinimide
HBTU O-benzotriazole-N,N,N’,N’-tetramethyluronium hexafluorophosphate
HOBt 1-hydroxybenzotriazole hydrate
MBTH 3-methyl-2-benzothiazolinonehydrazone
Nle (M) norleucine
OBOC one-bead-one-compound
PED-MS partial Edman degradation-mass spectrometry
PEGA polyethyleneglycol acrylamide
PITC phenyl isothiocyanate
PTP protein tyrosine phosphatase
pY phosphotyrosine
TFA trifluoroacetic acid
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Figure 1.
Histograms showing the sequence selectivity of HePTP (A), PTP-PEST (B), PTPH1 (C),
TCPTP (D), PTPD2 (E), PTPRB (F), PTPRC (G), PTPRD/Class I (H), and PTPRO (I) on
the N-terminal side of pY. The y axis represents the percentage of selected peptides that
contained a particular amino acid (x axis) at a given position within the peptide (pY-8 to
pY-1, on the z axis). Data shown were from libraries I and III for PTP-PEST, library II for
HePTP, PTPRC, and PTPRD, and library III for PTPH1, TCPTP, PTPD2, PTPRB, PTPRO.
M, Nle; Y, F2Y.
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Figure 2.
Histograms showing the C-terminal selectivity of HePTP (A), TCPTP/Class I (B), and
PTPD2/Class I (C) derived from Library IV. The y axis represents the percentage of selected
peptides that contained a particular amino acid (x axis) at a given position within the peptide
(pY+1 to pY+5, on the z axis). M, Nle; Y, F2Y.
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Figure 3.
Histograms showing the sequence selectivity of PTP-PEST (A), PTPRB (B), and PTPRO/
Class I (C) derived from library V. The y axis represents the percentage of selected peptides
that contained a particular amino acid (x axis) at a given position within the peptide (pY-5 to
pY+5, on the z axis). M, Nle.
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Figure 4.
Structure of C215S PTP1B in complex with nephrin peptide AWGPLpY1193 DEVQM. A)
The nephrin peptide was contoured with the Fobs – Fcalc omit map at 1.0 σ. B) Ribbon
diagram of the PTP1B–nephrin peptide complex. The Arg24 and Arg47 residues of PTP1B
(yellow) are shown in stick representation. C) Interactions between the nephrin peptide
(green) and PTP1B (yellow). Hydrogen bonds are shown as black dashed lines. D) The
electrostatic surface potential of PTP1B. Basic residues near the active site are shown in
blue and labeled. In (B) and (C), the side chain of Arg47 was truncated (to Ala) due to the
absence of clear electron density for the side chain.
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Figure 5.
Reaction progress curve showing the burst kinetics of PTPD1-catalyzed hydrolysis of pNPP
(20 mM) at 4 °C. Data were fitted to a double exponential equation (red, solid line) or to a
single exponential equation (green, dotted line). Fitting of the entire progress curve to the
mechanism in Scheme 1 using the double exponential equation: P = A • exp(-kburst • t) + B •
exp(-k1’ • t) + C • t + D, where kburst = k2 + k3, kcat = C/(ε • [E]) = k2 • k3/(k2 + k3). The data
shown is the average of three independent experiments performed under the same
conditions.
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Figure 6.
Proposed model showing regulation of cell signaling by PTPD1 (or PTPD2) under single-
turnover conditions. E, PTPD1 or PTPD2; S, pY substrate protein.
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Scheme 1.
PTP Kinetic Mechanisms
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Table 1
Peptide Libraries Employed in This Work
Library No. Library Design Amino Acid Composition at Random Positions (X)
I ASXXXXXpYAABBRM Ala, Arg, Asn, Asp, F2Y, Gly, Gln, Glu, His, Ile, Leu, Lys, Nle, Phe, Pro, Ser, Thr,
Trp, Val
II Alloc-AXXXXXXXXpYAABBRM Ala, Arg, Asn, Asp, Gly, Gln, Glu, His, Ile, Leu, Lys, Nle, Phe, Pro, Ser, Thr, Trp,
Val
III Alloc-ASXXXXXpYAABBRM Ala, Arg (10-fold reduced content), Asn, Asp, F2Y, Gly, Gln, Glu, His, Ile, Leu, Lys
(10-fold reduced content), Nle, Phe, Pro, Ser, Thr, Trp, Val
IV Alloc-AApYXXXXXNNBBRM Ala, Arg, Asn, Asp, F2Y, Gly, Gln, Glu, His, Ile, Leu, Lys, Nle, Phe, Pro, Ser, Thr,
Trp, Val
V Alloc-AXXXXXpYXXXXXNNBBRM Ala, Arg, Asn, Asp, Gly, Gln, Glu, His, Ile, Leu, Lys, Nle, Phe, Pro, Ser, Thr, Trp,
Val
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Table 3
Differential Preference of PTPs for Acidic over Neutral and Basic Sequencesa
enzyme Acidic/Basic Acidic/Neutral Neutral/Basic
PEST 150000 1100 140
SHP1 100000 1800 57
SHP2 46000 370 120
PTPH1 2600 20 130
HePTP 2500 42 59
PTP1B 1500 24 61
PTPD2 1300 8 160
PTPRB 1100 14 77
TCPTP 910 17 53
PTPRC 880 22 41
PTPRO 660 37 18
PTPD1 220 330 0.7
PTPRD 21 21 1
PTPRA 2 3 0.5
a
Ratio of kcat/KM values for peptides Ac-YDEDFpYDYEF-NH2 (acidic), Ac-SASASpYSASA-NH2 (neutral), and Ac-YRKRFpYRYKF-NH2
(basic).
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Table 7
Crystallographic and Refinement Statistics
X-ray Diffraction Data
Space group P21
Cell dimensions
  a (Å) 43.8
  b (Å) 88.7
  c (Å) 50.0
  β (°) 97.3
Resolution (Å) 19.95–1.74 (1.83–1.74)
No. observations 147,218
No. unique 38,860
Completeness (%) 99.7 (99.7)
I/σI 6.2 (1.9)
Rmerge 0.120 (0.744)
Refinement Statistics
Resolution (Å) 19.95–1.74
No. reflections 36891
Rwork/Rfree 0.170 / 0.207
No. non- hydrogen atoms 2740
Mean B factor (Å2) 24.7
Root-mean-square deviation for bond lengths (Å) 0.023
Root-mean-square deviation for bond angles (deg) 2.15
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Table 8
Side Chain Distances (Å) between Arg (in PTP1B) and Asp Residues (in pY Peptide)a
Asp position Arg47 Arg24
pY-3 0.88–7.0 (1.1–7.3) 14–24 (15–23)
pY-2 4.2–12 (3.7–11) 14–23 (15–24)
pY-1 0.94–11 (1.2–11) 8.2–17 (8.9–17)
pY+1 5.4–16 (6.0–15) 3.8–11 (4.2–11)
pY+2 3.5–14 (9.6–18) 7.2–14 (6.3–14)
pY+3 — (4.6–15) — (6.2–15)
pY+4 — (8.8–20) — (11–17)
a
Distances were derived from the structure of PTP1B bound with Ac-AWGPLpYDEVQM-NH2. Values in parenthesis were derived from the
structure of PTP1B bound with Ac-ELEFpYMDYE-NH2 (PDB file: 1EEO).
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